Hilltop Partners LLC Purchases 3,453 Shares of Johnson & Johnson $JNJ

Hilltop Partners LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 24.7% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 17,419 shares of the company’s stock after purchasing an additional 3,453 shares during the period. Johnson & Johnson comprises about 0.8% of Hilltop Partners LLC’s investment portfolio, making the stock its 23rd largest position. Hilltop Partners LLC’s holdings in Johnson & Johnson were worth $2,661,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Clark Asset Management LLC boosted its holdings in Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares during the last quarter. Treasurer of the State of North Carolina boosted its stake in shares of Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after buying an additional 94,957 shares during the last quarter. Apexium Financial LP boosted its stake in shares of Johnson & Johnson by 10.7% in the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB grew its holdings in shares of Johnson & Johnson by 2.9% in the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares during the period. Finally, Winnow Wealth LLC purchased a new stake in Johnson & Johnson during the second quarter valued at $295,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.8%

Shares of NYSE JNJ opened at $211.65 on Monday. The stock has a market capitalization of $509.93 billion, a price-to-earnings ratio of 20.43, a P/E/G ratio of 2.36 and a beta of 0.36. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm’s 50-day moving average price is $196.09 and its 200-day moving average price is $177.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $212.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s payout ratio is presently 50.19%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. The Goldman Sachs Group raised their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 target price for the company in a report on Monday, October 20th. Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, Morgan Stanley raised their price target on Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a report on Friday. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $207.55.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.